GlassScriptPhysician profile
Ahmed Hamdi Eldib
NPI 1801405147
$1,982.78
in general payments reported to CMS, 2019-2025
19 companies · $283 in 2025
The $283 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $82.70 · 2021: $21.95 · 2022: $39.58 · 2023: $226 · 2024: $1,330 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.56 |
| Education | $163.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $226.97 | 2023-2025 | Acthar |
| Amgen INC. | $221.11 | 2024-2025 | Tavneos, Enbrel, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.82 | 2024 | Ofev |
| Genzyme Corporation | $175.94 | 2024-2025 | |
| Ucb, INC. | $172.56 | 2023-2025 | Cimzia, Bimzelx |
| Sanofi-Aventis U.S. LLC | $163.99 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $135.74 | 2020-2025 | Saphnelo |
| Abbvie INC. | $124.99 | 2024 | |
| Glaxosmithkline, LLC. | $119.60 | 2024 | Benlysta |
| Alvogen INC | $98.05 | 2023-2024 | Teriparatide |
| Kiniksa Pharmaceuticals International, Plc | $96.33 | 2024 | Arcalyst |
| Aurinia Pharma U.S., INC. | $76.57 | 2023-2024 | Lupkynis |
| Pfizer INC. | $48.74 | 2020-2024 | |
| Fresenius Kabi USA, LLC | $36.11 | 2024 | Idacio |
| Celgene Corporation | $22.11 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21.95 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.81 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.77 | 2022 | |
| Octapharma USA, INC. | $14.62 | 2023 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Eldib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.